Editorial comment.
Oya
Mototsugu
M
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011494:Protein Kinases; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases
D000081082:Phosphoinositide-3 Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases